Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a worldwide pioneer in
the field of medical and industrial exoskeletons, and Genesis Rehab
Services (GRS), a leading provider of physical, occupational,
speech, and respiratory therapy, with a focus on the older adult
population, announced today their collaboration to study
opportunities for incorporating EksoGT™ in skilled nursing
facilities.
Through its EksoGTTM , the first FDA-cleared
wearable exoskeleton indicated for stroke and spinal cord injury
(SCI) rehabilitation, Ekso is already helping stroke and SCI
patients in hospital settings achieve early mobility and
independence. Now, using guidance from Genesis Rehab Services, Ekso
will learn more about post-acute rehabilitation settings to support
better patient outcomes in skilled nursing facilities.
Through a learning collaboration between
Genesis’ Layhill Center (Silver Spring, MD) and Ekso, the team is
working to:
- Define the needs and challenges of the post-acute care
industry.
- Investigate tactics to efficiently deploy and scale an
exoskeleton program.
- Determine the clinical and economic benefits for a new standard
of care.
- Quantify the economic case for adopting exoskeletons in
rehabilitation.
Thomas Looby, President and Chief Executive
Officer, remarked, “We are excited to learn from one of the most
innovative rehabilitation services providers in the world, and
would like to thank Sarah Thomas, Senior Director of Innovation for
GRS, for the vision and commitment to bringing our two
organizations together. In the United States alone, more than 2.4
million Medicare patients receive rehabilitation at nearly 15,000
skilled nursing facilitiesi. The leadership at Genesis has
demonstrated a visionary and strategic approach to incorporating
groundbreaking rehabilitation technology to further enhance patient
care and outcomes, increase efficiencies, and reduce costs for
payers at the more than 1,700 facilities it serves. Together, we
aim to redefine rehabilitation for the entire industry, and
ultimately to make exoskeleton gait rehabilitation a standard of
care.”
Dan Hirschfeld, President of Genesis Rehab
Services, commented, “We’re honored that Ekso recognizes us as an
innovative rehab services leader. We expect that Ekso’s
collaboration with our physical therapists at Layhill Center will
pave the way for additional opportunities to influence innovation
within the post-acute rehabilitation setting. We are excited to
quantify the potential benefits of exoskeleton gait rehabilitation
for our patients.”
About Genesis Rehab ServicesGenesis Rehab
Services (GRS) is a leading provider of physical therapy,
occupational therapy, speech therapy, respiratory therapy, and
wellness services, primarily for the older adult population. As one
of the largest and strongest rehab organizations in the country,
GRS partners with skilled nursing centers, assisted living
facilities, independent living facilities, hospitals, home health
companies, adult day care programs, and outpatient clinics to
provide comprehensive therapy services.
GRS employs over 17,000 therapists and
assistants in more than 1,700 locations. GRS operate in 46 states
and the District of Columbia, and touches 55,000 patients each day.
For more information, visit: www.genesisrehab.com.
About Ekso Bionics®Ekso Bionics
is a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical, industrial and defense applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe, to providing
research for the advancement of R&D projects intended to
benefit U.S. defense capabilities. The company is headquartered in
the Bay Area and is listed on the Nasdaq Capital Market under the
symbol EKSO. For more information, visit: www.eksobionics.com.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(ii) estimates or projection of financial results, financial
condition, capital expenditures, capital structure or other
financial items, (iii) the Company's future financial performance
and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company's current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing to
fund the Company's operations and necessary to develop or enhance
our technology, the significant length of time and resources
associated with the development of the Company's products, the
Company's failure to achieve broad market acceptance of the
Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com. The Company does not undertake to update these
forward-looking statements.
i OIG, Adverse Events in Rehabilitation
Hospitals: National Incidence Among Medicare Beneficiaries,
OEI-06-14-00100, July 2016. Accessed September 7, 2017:
https://oig.hhs.gov/oei/reports/oei-06-14-00110.pdf
Ekso Bionics Media Contact:Carrie
Yamond917-371-2320cyamond@lazarpartners.com
Ekso Bionics Investor Contact:Matthew
Ventimiglia212-599-1265investors@eksobionics.com
Genesis Media Contact: Jeanne
Moore 484-949-5647Jeanne.Moore@GenesisHCC.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024